Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
BJU International|March 30, 2010
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyJuan Barbastefano, Jorge A Garcia, Paul Elson, et al.
BMC Cancer|March 31, 2016
Response to post-axitinib treatment in patients with metastatic renal cell carcinomaNamita Chittoria, Housam Haddad, Paul Elson, et al.
Seminars in Oncology Nursing|November 26, 2023
The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell CarcinomaSara Parreira, Kathleen Burns, Nancy Moldawer, et al.
Clinical Genitourinary Cancer|October 16, 2013
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinibMohamed E Salem, Shetal N Shah, Paul Elson, et al.
Cancer|December 6, 2011
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcomeSarmad Sadeghi, Laurence Albiges, Laura S Wood, et al.
Urologic Oncology|August 23, 2018
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy eraYu-Wei Chen, Moshe C Ornstein, Laura S Wood, et al.
Journal for Immunotherapy of Cancer|May 18, 2019
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapyMoshe C Ornstein, Laura S Wood, Brian P Hobbs, et al.
Clinical Genitourinary Cancer|August 18, 2020
Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell CarcinomaRuby Gupta, Moshe Chaim Ornstein, Hong Li, et al.
Targeted Oncology|March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialBrian I Rini, David I Quinn, Michael Baum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2017
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaMoshe C Ornstein, Laura S Wood, Paul Elson, et al.
Pageof 4